Sandoz Scientific Standalone Event in Poland “Reach Targets – Save Lives”

  • Sandoz Scientific Standalone Event “Reach Targets – Save Lives” aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA). 
  • First ever event utilizing digital platforms to reach healthcare professionals with state-of-art information shared by internationally recognized and trusted Key Opinion Leaders (KOL).
  • The event was also broadcasted for medical experts in Slovenia.
23. 3. 2017

Sandoz held a Scientific Standalone Event “Reach Targets – Save Lives” on March 21, in Warsaw, Poland. This event aims to increase access to valuable medical information in the field of cardiovascular therapies to healthcare professionals across the CEEMEA region.

At the event Francesco Balestrieri, Head of Sandoz CEEMEA said: “Our goal at Sandoz is to increase access to high-quality medicines, medical information and medical capacity to millions of people every year. To achieve this we are constantly looking for new and innovative ways to engage with the medical community.” He added: “This event on cardiovascular is testimony of our commitment to make medical information available to as many specialists as possible. We fundamentally believe that health outcomes for patients can be improved if more people are better trained to prevent, diagnose and treat diseases appropriately.”

It is a commonly recognized fact that cardiovascular diseases are a leading cause of death worldwide for recent decades1-4. There are different reasons for such alarming statistics, but they can be highlighted with two common denominators. One important group is undiagnosed and untreated patients and the other group of treated, but ineffectively controlled patients. Both groups of patients are not reaching target values that are safer for them, especially long-term. To address these two major reasons of cardiovascular mortality Sandoz in collaboration with local medical doctors’ communities from CEEMEA countries has chosen four focus topics for the event: 

  • Dyslipidaemia 
  • Hypertension 
  • Chronic kidney disease 
  • Patient compliance 

The “Reach Targets – Save Lives” event was organized on-site in Warsaw and broadcasted to more than 20 countries in the CEEMEA region simultaneously. In these remote locations, local KOLs were attending the broadcasted event and were encouraged to share the content through local events. 

The event was also broadcasted for healthcare experts in Slovenia. With this event Sandoz increased access to medical information for healthcare professionals, whose aim is to benefit the patients in Slovenia.  


  1. World Health Organization, Cardiovascular diseases (CVDs)
  2. Fuster V et al. National Academy of Sciences. Epidemiology of Cardiovascular Disease. 2010. Accessed 09-02-2017.
  3. Heart disease and stroke statistics— 2015 update: a report from the American Heart Association [published online ahead of print December 17, 2014]. Circulation. doi: 10.1161/CIR.0000000000000152.
  4. Roth GA et al. Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality. N Engl J Med 2015;372:1333-41.
* * *

Lek, a Sandoz company, is one of the key pillars of the second-largest generic pharmaceutical company globally. Its role within Sandoz is to act as: a leading global development center for technologically demanding products and technologies; a key global manufacturing center for active pharmaceutical ingredients and medicines; a competence center for the development of vertically integrated products; a Sandoz competence center in the field of development and manufacturing of biosimilar active ingredients and products; a supply center for the markets of Central and Eastern Europe (CEE), South East Europe (SEE) and the Commonwealth of Independent States (CIS), and is responsible for marketing and sales of Sandoz products on the Slovenian market. For further information, please visit

Sandoz is a global leader in generic and biosimilar pharmaceuticals. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people’s lives. We contribute to society’s ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2015 sales of USD 10.1 billion. In 2015, our products reached more than 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.
Sandoz is on Twitter. Sign up to follow @Sandoz_global at (link is external).

For further details visit

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9 billion (USD 8.4 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 155 countries around the world. For more information, please visit

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32